What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate

Epilepsia. 2009 Dec:50 Suppl 12:49-50. doi: 10.1111/j.1528-1167.2009.02366.x.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acetamides / pharmacology
  • Acetamides / therapeutic use
  • Animals
  • Anticonvulsants / pharmacology
  • Anticonvulsants / therapeutic use*
  • Carbamates / pharmacology
  • Carbamates / therapeutic use
  • Disease Models, Animal
  • Fructose / analogs & derivatives
  • Fructose / pharmacology
  • Fructose / therapeutic use
  • Humans
  • Lacosamide
  • Pyrroles / pharmacology
  • Pyrroles / therapeutic use
  • Pyrrolidinones / pharmacology
  • Pyrrolidinones / therapeutic use
  • Rats
  • Receptors, AMPA / antagonists & inhibitors
  • Status Epilepticus / diagnosis
  • Status Epilepticus / drug therapy*
  • Tetrahydroisoquinolines / pharmacology
  • Tetrahydroisoquinolines / therapeutic use
  • Topiramate
  • Treatment Outcome

Substances

  • Acetamides
  • Anticonvulsants
  • Carbamates
  • Pyrroles
  • Pyrrolidinones
  • Receptors, AMPA
  • S-2-O-carbamoyl-1-o-chlorophenyl-ethanol
  • SPD 502
  • Tetrahydroisoquinolines
  • Topiramate
  • Fructose
  • Lacosamide
  • brivaracetam